Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y7VP
|
|||
| Former ID |
DIB014871
|
|||
| Drug Name |
VRS-317
|
|||
| Synonyms |
HGH-XTEN; Human growth hormone-XTEN; RPEG HGH (injectable, growth deficiency), Versartis; Recombinant PEGylated human growth hormone (injectable, growth deficiency), Versartis
Click to Show/Hide
|
|||
| Indication | Growth hormone deficiency [ICD-11: 5A61.3] | Phase 3 | [1] | |
| Company |
Versartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Somatotropin (GH1) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Neuroactive ligand-receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Reactome | Prolactin receptor signaling | |||
| Growth hormone receptor signaling | ||||
| WikiPathways | Endochondral Ossification | |||
| Prolactin receptor signaling | ||||
| Growth hormone receptor signaling | ||||
| Adipogenesis | ||||
| Synthesis, Secretion, and Deacylation of Ghrelin | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02339090) Comparison of Long-acting Growth Hormone VRS-317 to Daily Growth Hormone in Pediatric GHD Patients. U.S. National Institutes of Health. | |||
| REF 2 | Company report (Versartis) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.